Exelixis (EXEL) Stock
Cancer drug maker with a commercial treatment portfolio. Here's the price, business snapshot, and what's worth knowing about Exelixis in October 2026.
Exelixis, Inc. (EXEL) is a clinical-stage biotechnology company focused on developing and commercialising oncology therapies. Its best-known product is cabozantinib, approved for several cancer indications and a core revenue driver, while Exelixis pursues additional indications and combination studies to expand clinical use. The company operates a mix of internal development and partnering arrangements to fund research and broaden geographic reach. Investors should note the typical biotech profile: potential for significant upside from successful trials and approvals, balanced by regulatory, clinical and competitive risks that can materially affect valuation. Financial performance can be volatile and is often linked to milestone payments, royalties and product sales. With a market capitalisation near $9.7 billion, Exelixis is a meaningful mid‑cap biotech but remains exposed to trial outcomes, patent timelines and pricing pressures. This information is educational, not personal investment advice; suitability depends on individual circumstances and investments can fall as well as rise.
Exelixis (EXEL) Stock Forecast
Analyst price target, next 12 months
$43.44
-27.4% vs today's $59.86
Price range over the last 12 months
Close to its 12-month high
Analysts covering Exelixis have a consensus 12-month target of $43.44, below the current price of $59.86.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 11 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Exelixis' stock with a target price of $43.44, indicating limited growth.
Financial Health
Exelixis is performing well with strong revenue and cash flow, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical catalysts ahead
Ongoing trials and potential label expansions could drive re‑rating, though outcomes are uncertain and can move the share price sharply.
Core drug focus
Cabozantinib is central to revenue and pipeline strategy; success in new indications could extend commercial life but competition is strong.
Partnership reach
Collaborations and licensing deals help fund development and broaden market access, though partner terms and regional reimbursement affect returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
